Veradermics, Incorporated (MANE) Stock
Key stats
- Market cap
- $6.61B
- Price / Earnings ratio
- -74.4x
- EPS (TTM)
- -$111.91
- Volume
- Loading
- 52-week high
- $152.82
- 52-week low
- $32.00
Source: third-party data provider, as of November 13, 2026
Compare with MANE
Recent news
Veradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth Results
Veradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth Results
MANE
Veradermics' oral hair-loss drug shown to boost hair growth in late-stage study
Veradermics' oral hair-loss drug shown to boost hair growth in late-stage study
MANE
Veradermics' Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304' Clinical Trial in Male Pattern Hair Loss
Veradermics' Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304' Clinical Trial in Male Pattern Hair Loss
MANE
Veradermics to Hold Conference Call to Discuss Topline Results from Phase 3 ‘304' Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
Veradermics to Hold Conference Call to Discuss Topline Results from Phase 3 ‘304' Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
MANENews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 67.64
- MACD 12/26/9
- 7.24
- EMA 9 of MACD
- 6.20
- MACD histogram
- 1.04
- SMA 50
- $120.86
- Price above SMA 50
- EMA 50
- $125.45
- Price above EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news
Veradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth Results
Veradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth Results
MANEVeradermics' oral hair-loss drug shown to boost hair growth in late-stage study
Veradermics' oral hair-loss drug shown to boost hair growth in late-stage study
MANEVeradermics' Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304' Clinical Trial in Male Pattern Hair Loss
Veradermics' Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304' Clinical Trial in Male Pattern Hair Loss
MANEVeradermics to Hold Conference Call to Discuss Topline Results from Phase 3 ‘304' Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
Veradermics to Hold Conference Call to Discuss Topline Results from Phase 3 ‘304' Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
MANE
Veradermics to Present at Upcoming September Investor Conferences
Veradermics to Present at Upcoming September Investor Conferences
MANE
Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
MANE
Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302' in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy
Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302' in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy
MANE
Why Is MANE Stock Rising Today?
Why Is MANE Stock Rising Today?
MANE
Veradermics Hair Loss Pill Shows Strong Phase II Signal in Women
Veradermics Hair Loss Pill Shows Strong Phase II Signal in Women
MANE
Veradermics' Oral VDPHL01 Delivers Positive Study ‘207' Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306' Readout
Veradermics' Oral VDPHL01 Delivers Positive Study ‘207' Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306' Readout
MANENews tone: automated (AI) classification of the article's content, not a price prediction.
About Veradermics, Incorporated
The company is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is on developing improved treatments for pattern hair loss (PHL), a condition affecting approximately 50 million men and 30 million women in the United States. Current treatment options for PHL are limited and are therefore consistently associated with high rates of treatment failure, patient dissatisfaction, and treatment discontinuation. Patients and healthcare providers routinely identify several shortcomings in existing therapies, including a slow onset of hair growth, inconsistent results, and insufficient hair density to meet patient expectations.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Reid Waldman M.D. | CEO & Director | 1995 |
| Mr. Dominic Carrano CPA | CFO & Treasurer | 1986 |
| Dr. Timothy Durso M.D. | Chief Technical Officer | 1990 |
| Mr. Michael V. Greco J.D. | General Counsel & Secretary | 1973 |
| Mr. Karl Pruss | Senior Director of Manufacturing Sciences & Technology | — |
| Mr. Mark Neumann | Chief Commercial & Strategy Officer | 1964 |
| Ms. Erika Sipperly CPA | Controller | — |
| Dr. Michael Smolinski Ph.D. | Vice President of Development & Scientific Operations | 1978 |
| Mr. Aron Shapiro | Vice President of Clinical Development & Regulatory Affairs | 1978 |
| Mr. Brian Trautman | Director of CMC Project Management | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 67.64
- MACD 12/26/9
- 7.24
- EMA 9 of MACD
- 6.20
- MACD histogram
- 1.04
- SMA 50
- $120.86
- Price above SMA 50
- EMA 50
- $125.45
- Price above EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $150.00
- Average
- $175.25
- High
- $204.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +21.5 | +35.5 | +68.4 | -0.1 | +21.1 | -18.3 | -3.4 | +24.3 | +19.2 | +20.9 |
Corporate actions
Upcoming
No upcoming corporate actions for MANE
